April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Enhanced allosensitization following corneal allograft transplantation in dry eye disease recipients
Author Affiliations & Notes
  • Antonio Di zazzo
    Ophthalmology, Harvard Medical School, Boston, MA
  • Jing Hua
    Ophthalmology, Harvard Medical School, Boston, MA
  • William Stevenson
    Ophthalmology, Harvard Medical School, Boston, MA
  • Takenori Inomata
    Ophthalmology, Harvard Medical School, Boston, MA
  • Tina Shiang
    Ophthalmology, Harvard Medical School, Boston, MA
  • Thomas H Dohlman
    Ophthalmology, Harvard Medical School, Boston, MA
  • Sang-Mok Lee
    Ophthalmology, Harvard Medical School, Boston, MA
  • Masahiro Omoto
    Ophthalmology, Harvard Medical School, Boston, MA
  • Qiuang Zhang
    Ophthalmology, Harvard Medical School, Boston, MA
  • Reza Dana
    Ophthalmology, Harvard Medical School, Boston, MA
  • Footnotes
    Commercial Relationships Antonio Di zazzo, None; Jing Hua, None; William Stevenson, None; Takenori Inomata, None; Tina Shiang, None; Thomas Dohlman, None; Sang-Mok Lee, None; Masahiro Omoto, None; Qiuang Zhang, None; Reza Dana, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3218. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Antonio Di zazzo, Jing Hua, William Stevenson, Takenori Inomata, Tina Shiang, Thomas H Dohlman, Sang-Mok Lee, Masahiro Omoto, Qiuang Zhang, Reza Dana; Enhanced allosensitization following corneal allograft transplantation in dry eye disease recipients. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3218.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Results from our previous studies have confirmed dry eye disease (DED) as a risk factor for corneal allograft rejection. Allosensitization mediated through antigen-presenting cells (APC) in the draining lymph nodes (DLN) plays a large role in determining corneal allograft survival. In this study, we investigated APC trafficking in DED recipients and the subsequent immune sensitization against alloantigens

Methods: DED was induced in female Balb/c mice using the controlled environment chamber and subcutaneous scopolamine injections over two weeks. CD45.1 + congenic transgenic donor corneas on a C57Bl/6 background were grafted onto DED Balb/c mice. Normal Balb/c mice residing in room air underwent corneal transplantation and served as controls. DLNs were isolated 24 hours after transplantation for flow cytometric analysis: CD45.1 staining was used to detect donor-derived APCs and YAe antibody was used to identify alloantigen-bearing recipient APCs. Furthermore, delayed-type hypersensitivity (DTH) assay was performed on postoperative day 8

Results: Flow cytometry analysis demonstrated increased frequencies of both CD45.1+ and YAe+ cells in the DLNs of DED recipients 24 hours after allograft transplantation compared with control mice (CD45.1+: 0.53% vs. 0.35%; YAe+: 0.94% vs. 0.62%). Among CD11c+ APCs in the DLNs, DED recipients displayed more donor-derived cells (CD45.1+: 56.6% vs. 19.56%) and the APCs were more mature (MHCII+: 61.91% vs. 23.16%). DED recipients also had a greater CD45.1+ MHCII+ population (56% vs.19.2%). APC maturation was confirmed by higher frequencies of CD80 and CD86 on CD45.1+ cells in DLNs of DED recipients. Ear swelling in DTH assay was significantly higher in DED vs. control mice (3.4 µm vs. 1.7 µm, n=5, p=0.0023)

Conclusions: Our data demonstrate that increased APC maturation and trafficking in DED recipients may contribute to the enhanced allosensitization and furthermore a higher rejection rate

Keywords: 480 cornea: basic science • 741 transplantation • 555 immunomodulation/immunoregulation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×